Compare Neurocrine Biosciences Inc (NBIX) vs Pinterest Inc (PINS) Price & Performance

Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.

Pinterest (PINS) trades at $22.90, down 6.03% over 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 EPS of $0.43, beating estimates of $0.36, driven by 18% revenue growth and record monthly active users. However, the stock faces pressure from lukewarm Q3 revenue guidance and competitive ad market concerns.

The outlook remains positive with strong analyst support—54% recommend Buy—and a $28.69 consensus price target implying 25% upside. Key risks include intense advertising competition and potential growth deceleration, but fundamentals are solid with revenue climbing to $4.22B in 2025 and a robust 79.47% gross margin.